Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model.
about
Immunotherapy for patients with advanced pancreatic carcinoma: A promising treatmentChemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanismAutologous cytokine-induced killer cell transfusion increases overall survival in advanced pancreatic cancer.Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancerImmunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model.Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer.Establishment of an orthotopic pancreatic cancer mouse model: cells suspended and injected in Matrigel.Role of heparanase in radiation-enhanced invasiveness of pancreatic carcinoma.Antigen-loaded dendritic cell migration: MR imaging in a pancreatic carcinoma model.Macrophage polarization in pancreatic carcinoma: role of heparanase enzyme.Current immunotherapeutic approaches in pancreatic cancer.Progression of Large Lymphoma Is Significantly Impeded with a Combination of Gemcitabine Chemotherapy and Dendritic Cells Intra-Tumor Vaccination.Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell TherapyDendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinomaDendritic cell-based cancer vaccination: quo vadis?Chemo-immunotherapy mediates durable cure of orthotopic KrasG12D/p53-/- pancreatic ductal adenocarcinomaRole of immune cells in pancreatic cancer from bench to clinical application: An updated reviewStrategies to relieve immunosuppression in pancreatic cancer.A pancreatic tumor-specific biomarker characterized in humans and mice as an immunogenic onco-glycoprotein is efficient in dendritic cell vaccination.The importance of correctly timing cancer immunotherapy.Low-dose chemotherapeutic agents regulate small Rho GTPase activity in dendritic cells.Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(+) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model.Dendritic cells fused with different pancreatic carcinoma cells induce different T-cell responsesAn ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma.Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrationsIntratumoral Mistletoe (Viscum album L) Therapy in Patients With Unresectable Pancreas Carcinoma: A Retrospective Analysis.Targeted activation of melanoma differentiation-associated protein 5 (MDA5) for immunotherapy of pancreatic carcinoma.Dendritic cells based immunotherapy.Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: a multicenter analysis.Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells.
P2860
Q28074428-ACA758E4-058C-4227-95D6-193335D8DFF3Q28384980-9DAE067E-9A58-49A2-B2C2-0F5B7CC711B1Q33429758-1DE80F05-EC2D-4253-9065-332B9B1E2638Q33602876-FD74799C-F0DA-44C4-8AB5-0CD0AFF2592FQ33613430-D591C2D6-846D-461F-A065-C20B0B7EB802Q33820442-E2460F55-7BF6-487B-8718-125679C6C53EQ33948383-003188DE-8B0E-41B5-B738-028A3E279023Q34762351-372964F6-9335-4532-B7FD-01FD7DD80A2EQ35038974-4C319DDC-E249-4EB6-9716-9A4B24EF3562Q35102577-AC18A014-78B2-4207-A9CC-0C7D1E60CC39Q35212837-71DC00F7-BE6C-4FAB-9DD3-18C4E7FC5AFBQ35693324-11286FD3-A263-40A7-8703-43EF0A3C4869Q36173500-081562C8-7BAD-4ED9-A1F1-7394B68912EFQ36883666-CB067335-5E4C-445B-B05C-D23B81728B9EQ37259624-D876718A-83A0-47CE-A784-8EFB765C9974Q37308212-85AE5E3F-1A15-469B-8626-46131C82357CQ37606102-10D557E0-2965-4789-95CC-C0C3D0AC3FA4Q38445328-6138BFE6-D89F-4BF2-83F5-96549C75153AQ38832639-39D3CDD9-1100-4E2F-9DF2-48D796309FB4Q38995979-9600BC76-1F7E-4391-A182-0DF5A50146A5Q39000198-BE83DD57-162E-4D47-83AF-16C696EDB420Q39037817-A2C52C76-75D6-485D-B477-997F6D8A735FQ39200045-365138BA-64A1-4022-A3E0-BD708C7043FFQ39703281-49284660-BD92-4995-806E-F696494B3C58Q39826691-D1B08362-9274-4D61-92CC-231CDBCDCBA4Q40223950-363F92FC-EB64-4043-829C-D8FF339F38D0Q41182217-035B9C00-A2E8-4E80-95A2-A1E6BBFF281BQ43043935-2286DEB3-808B-4F60-82F7-3941AD164600Q43800976-72B901E7-0AC3-4708-836E-4B813903DCC2Q55364385-EE3A8E8D-4202-49AC-B046-79ED4CCAB14E
P2860
Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Dendritic cell-based vaccinati ...... ne pancreatic carcinoma model.
@ast
Dendritic cell-based vaccinati ...... ne pancreatic carcinoma model.
@en
type
label
Dendritic cell-based vaccinati ...... ne pancreatic carcinoma model.
@ast
Dendritic cell-based vaccinati ...... ne pancreatic carcinoma model.
@en
prefLabel
Dendritic cell-based vaccinati ...... ne pancreatic carcinoma model.
@ast
Dendritic cell-based vaccinati ...... ne pancreatic carcinoma model.
@en
P2093
P2860
P356
P1433
P1476
Dendritic cell-based vaccinati ...... ne pancreatic carcinoma model.
@en
P2093
F Bauernfeind
P2860
P304
P356
10.1136/GUT.2006.108621
P407
P577
2007-03-29T00:00:00Z